4.4 Article

MPTP administration increases plasma levels of acute phase proteins in non-human primates (Macaca fascicularis)

Journal

NEUROSCIENCE LETTERS
Volume 463, Issue 1, Pages 37-39

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2009.07.069

Keywords

C-reactive protein (CRP); Serum amyloid A (SAA); Haptoglobin (HP); Parkinson's disease; Neuroinflammation; Dopamine; Neuronal degeneration

Categories

Funding

  1. Spanish Ministry of Science (SAF) [2004 07656 C02-02]
  2. Fundacion Seneca [FS/05662/PI/07]
  3. CIBERNED (Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas)

Ask authors/readers for more resources

Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the Substantia Nigra pars compacta (SNpc). Parkinsonian patients and animal models of PD show inflammatory phenomena such as microglial activation and cytokine production that could modulate the progression of the disease, since they play a crucial role in the degenerative process. Since acute phase proteins (APPs) are involved in a number of homeostatic alterations and inflammatory processes, we analyzed the levels of APPs in primates before and after treatment with MPTP. A significant increase in C-reactive protein (CRP), serum amyloid A (SAA) and haptoglobin (HP) levels after MPTP treatment. These results demonstrate that MPTP induces a systemic generalized inflammatory reaction after specific dopaminergic neurotoxicity insult, suggesting that the inflammatory process in Parkinsonism may affect other immune-inflammatory responses outside the brain. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available